Immunic CEO says Q2 results "couldn't be better"
Immunic Inc (NASDAQ:IMUX) president and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive following the release of the Munich-based biotechnology...
Stay updated with breaking news from Immunic Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Immunic Inc (NASDAQ:IMUX) president and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive following the release of the Munich-based biotechnology...
– Preclinical Data Published in the Journal of Medicinal Chemistry Identifies Vidofludimus Calcium as a Potent Nurr1 Activator, Reinforcing Neuroprotective...
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
Investing in small companies, penny stocks, micro-cap or even small-cap companies went out of fashion as soon as the financial markets started to take a beating amid interest rate hikes.
Wedbush reiterated their outperform rating on shares of Immunic (NASDAQ:IMUX – Free Report) in a report issued on Thursday morning, Benzinga reports. Wedbush currently has a $5.00 price target on the stock. Separately, StockNews.com began coverage on Immunic in a research report on Thursday, May 18th. They issued a sell rating on the stock. One […]